Recursion Pharmaceuticals, Inc. (RXRX) stock
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
Recursion Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Recursion Pharmaceuticals's enterprise value was $1.39B on Nov 11, 2026, against $1.63B a year earlier. Over the last 5 years it ranged from $352.60M to $2.75B, with a median of $1.38B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.39B | +1.5% |
| 2025 | Dec 31, 2025 | $1.37B | -10.6% |
| 2024 | Dec 31, 2024 | $1.53B | -12.1% |
| 2023 | Dec 29, 2023 | $1.74B | +97.9% |
| 2022 | Dec 30, 2022 | $877.77M | -61.8% |
| 2021 | Dec 31, 2021 | $2.30B | – |
See a number that looks wrong?